Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study <scp>TILOT</scp>-Reference-Cited by-同舟云学术

Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT

Published:2022-09-23 Issue:1 Volume:37 Page:85-92
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Tsianakas Athanasios¹,Schwichtenberg Uwe²,Pierchalla Peter³,Hinz Torsten⁴,Diemert Sebastian⁵,Korge Bernhard⁶

Affiliation:

1. Fachklinik Bad Bentheim Bad Bentheim Germany

2. Derma Nord Hautarztpraxen Bremen Germany

3. Hautärzte in Recklinghausen Recklinghausen Germany

4. Zentrum für Hautgesundheit Neuwied Germany

5. Almirall Hermal GmbH Reinbek Germany

6. Hautarztpraxis Düren Düren Germany

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.18572

Reference40 articles.

1. The global state of psoriasis disease epidemiology: a workshop report

2. The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study

3. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives;Feldman SR;Am Health Drug Benefits,2016

4. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas

5. Long-term topical management of psoriasis: the road ahead

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alopecia areata sparing vitiligo: Another Renbök phenomenon;Indian Journal of Dermatology, Venereology and Leprology;2024-09-07

2. A 3-Year Experience with Tildrakizumab Treatment for Patients with Plaque Psoriasis in Clinical Practice;Dermatology and Therapy;2024-08-27

3. What Is New in Nail Psoriasis?;Skin Appendage Disorders;2024-07-22

4. Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world setting;Journal of Dermatological Treatment;2024-07-22

5. Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review;Dermatology and Therapy;2024-07-16